Indoco Remedies (INDOCO.NS) Stock Price

Indoco Remedies Price

NSE·CLOSED
249.00
​
Market closed

Over the last 19 years Indoco Remedies grew revenue by 9.6% annually, reaching 18.45 B INR. Earnings per share have grown at 5.6% per year over the last 17 years. For Indoco Remedies, the net margin of -5.3% is down versus 10.3% a few years ago. At today's price the dividend yield works out to roughly 0.08%. The payout ratio is around 12% of earnings. The consensus 12-month price target for Indoco Remedies is 261.63 INR, about 5.1% above where the stock trades today. Of 9 analysts, 1 rate the stock a buy — an overall Sell consensus.

Indoco Remedies stock price

Access this data via the Eulerpool API

Indoco Remedies business model & stock analysis

Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra and currently employs 6,101 full-time employees. The company went IPO on 2005-01-07. The firm is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm offers medicines in multiple therapeutic categories, such as diabetology, respiratory, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders and primary care medicine. Its products/brands include Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel among others. The firm caters to both domestic and international markets. Its subsidiaries include Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited.

Frequently asked questions about Indoco Remedies

Analysts currently set an average price target of 264.44 INR for the Indoco Remedies stock (median: 261.63 INR), implying +6.2 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the Indoco Remedies stock: 1 recommend buying, 4 holding and 4 selling.

Converted at the current exchange rate, the Indoco Remedies share trades at 2.30 EUR (249.00 INR).

The Indoco Remedies share (INDOCO.NS) is listed on 2 stock exchanges, including: NSE (Indien) (INDOCO.NS).

The revenue of Indoco Remedies is 18.45 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Indoco Remedies is -987.00 M INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Indoco Remedies is currently -23.13. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Indoco Remedies stock.

The price-to-sales ratio (P/S) of Indoco Remedies is currently 1.24. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Indoco Remedies stock.

The Eulerpool Quality Score for Indoco Remedies is 1/10.

The ISIN of Indoco Remedies is INE873D01024. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Indoco Remedies is INDOCO.NS. The ticker symbol is used to trade Indoco Remedies shares on the stock exchange.

Fair ValueTerminal
256.47 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
3.02 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website indoco.com
Country
Currency
INR
Initial public offering
Jan 7, 2005
ISIN
INE873D01024
Cusip
Y3939C106
Market capitalization
22.96 B INRLarge Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee 2027
53.55
P/Ee 2028
21.06
P/S
P/Se
1.12
EV/EBIT
218.86
P/B Ratio
2.44
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-4.86 %
Gross Margin
40.72 %
EBIT Margin
0.83 %
Net Margin
-5.35 %
EPS (Earnings Per Share)
-10.77 INR
Net Debt / EBIT
69.30
Debt/Equity
1.16
Dividend
Dividend yield
0.08 %
Est. Dividend Yield
0.08 %
Payout Ratio
12.19 %
Dividend growth Ø5Y
-33.17 %
Dividend payments per year
1
Dividend paid since
21 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
20.00 %
Last updated Oct 5, 2026, 4:38 PM

Indoco Remedies Peer Group

Indoco Remedies Ticker

BSE · INDOCO.BONSE INDIA · INDOCO.NS

Indoco Remedies FIGI

INDR:IN · BBG000QNB9N3INDR:IB · BBG000QNBBN8INDR:IS · BBG000QNBCF5INDR:IG · BBG003NW7D47

All fundamentals and in-depth analysis of Indoco Remedies

Our stock analysis for Indoco Remedies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Indoco Remedies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.